These findings support the concept currently being tested in clinical trials that promoting ER:PR-B interactions by therapeutic administration of a progestogen may be an effective adjuvant treatment strategy for ER+ breast cancer.28,45,46 Indeed, assessment of ER:PR-B interactions using our new assay may be a means of monitoring treatment response in those trials. The gene discussed is RB1; the disease is breast carcinoma.